Warfarin-associated bleeding events and concomitant use of potentially interacting medicines reported to the Norwegian spontaneous reporting system

British Journal of Clinical Pharmacology

Volumn 71, Issue 2, 2011, Pages 254-262

  Narum, Sigrid ^a   Solhaug, Vigdis ^a   Myhr, Kirsten ^a   Johansen, Per Wiik ^a   Brørs, Odd ^a   Kringen, Marianne Kristiansen ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Adverse drug reactions; Anticoagulants; Bleeding; Drug interactions; Spontaneous reporting system; Warfarin

Indexed keywords

ACECLOFENAC; ACETYLSALICYLIC ACID; ADALIMUMAB; ALENDRONIC ACID; ALLOPURINOL; ALTEPLASE; AMIODARONE; AMOXICILLIN; AMPICILLIN; CEFALEXIN; CEFTRIAXONE; CIPROFLOXACIN; CITALOPRAM; CLARITHROMYCIN; CORTICOSTEROID; COTRIMOXAZOLE; DALTEPARIN; DEXTROPROPOXYPHENE; DICLOFENAC; DICLOXACILLIN; DOXYCYCLINE; ENOXAPARIN; ERYTHROMYCIN; ESCITALOPRAM; HEPARIN; PARACETAMOL; SERTRALINE; TRAMADOL; UNINDEXED DRUG; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; DRUG INDICATION; DRUG SURVEILLANCE PROGRAM; FEMALE; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; NORWAY; PHARMACODYNAMICS; PRIORITY JOURNAL;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FEMALE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; NORWAY; WARFARIN;

EID: 78650976422     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2010.03827.x     Document Type: Article

References (38)

1. Breen AB, Vaskinn TE, Reikvam A, Skovlund E, Lislevand H, Madsen S. [Warfarin treatment and bleeding] [Norwegian]. Tidsskr Nor Laegeforen 2003; 123: 1835-7.
2. The Norwegian Medicines Agency. Årsrapport 2005 [Annual Report 2005]. [Norwegian]. Internet 2006. Available at (last accessed 8 November 2010).
3. Wester K, Jonsson A, Spigset O, Hagg S. Spontaneously reported fatal suspected adverse drug reactions: a 10-year survey from Sweden. Pharmacoepidemiol Drug Saf 2007; 16: 173-80.
4. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-9.
5. Leone R, Sottosanti L, Luisa IM, Santuccio C, Conforti A, Sabatini V, Moretti U, Venegoni M. Drug-related deaths: an analysis of the Italian spontaneous reporting database. Drug Saf 2008; 31: 703-13.
6. Liu BA, Knowles SR, Mittmann N, Einarson T, Shear NH. Reporting of fatal adverse drug reactions. Can J Clin Pharmacol 2001; 8: 84-8.
7. Thiessard F, Roux E, Miremont-Salame G, Fourrier-Reglat A, Haramburu F, Tubert-Bitter P, Begaud B. Trends in spontaneous adverse drug reaction reports to the French pharmacovigilance system (1986-2001). Drug Saf 2005; 28: 731-40.
8. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007; 115: 2689-96.
9. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 1996; 348: 423-8.
10. Gasse C, Hollowell J, Meier CR, Haefeli WE. Drug interactions and risk of acute bleeding leading to hospitalisation or death in patients with chronic atrial fibrillation treated with warfarin. Thromb Haemost 2005; 94: 537-43.
11. Buresly K, Eisenberg MJ, Zhang X, Pilote L. Bleeding complications associated with combinations of aspirin, thienopyridine derivatives, and warfarin in elderly patients following acute myocardial infarction. Arch Intern Med 2005; 165: 784-9.
12. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 144-52.
13. Hallas J, Dall M, Andries A, Andersen BS, Aalykke C, Hansen JM, Andersen M, Lassen AT. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726.
14. Clinard F, Sgro C, Bardou M, Hillon P, Dumas M, Kreft-Jais C, Escousse A, Bonithon-Kopp C. Association between concomitant use of several systemic NSAIDs and an excess risk of adverse drug reaction. A case/non-case study from the French Pharmacovigilance system database. Eur J Clin Pharmacol 2004; 60: 279-83.
15. Penning-van BF, Erkens J, Petersen KU, Koelz HR, Herings R. Main comedications associated with major bleeding during anticoagulant therapy with coumarins. Eur J Clin Pharmacol 2005; 61: 439-44.
16. Schalekamp T, Klungel OH, Souverein PC, de BA. Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008; 168: 180-5.
17. Wallerstedt SM, Gleerup H, Sundstrom A, Stigendal L, Ny L. Risk of clinically relevant bleeding in warfarin-treated patients - influence of SSRI treatment. Pharmacoepidemiol Drug Saf 2009; 18: 412-6.
18. Penning-van Beest FJ, Koerselman J, Herings RM. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci 2007; 29: 671-5.
19. Wittkowsky AK, Boccuzzi SJ, Wogen J, Wygant G, Patel P, Hauch O. Frequency of concurrent use of warfarin with potentially interacting drugs. Pharmacotherapy 2004; 24: 1668-74.
20. Howard R, Avery A, Bissell P. Causes of preventable drug-related hospital admissions: a qualitative study. Qual Saf Health Care 2008; 17: 109-16.
21. Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 2007; 63: 136-47.
22. Glassman PA, Simon B, Belperio P, Lanto A. Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Med Care 2002; 40: 1161-71.
23. Ronning M. A historical overview of the ATC/DDD methodology. WHO Drug Information 2002; 16: 233-4.
24. Edwards IR, Aronson JK. Adverse drug reactions: definitions, diagnosis, and management. Lancet 2000; 356: 1255-9.
25. Foreningen for utgivelse av Norsk legemiddelhåndbok. Interaksjonsliste (Interactions). In: Norsk Legemiddelhåndbok for Helsepersonell (The Norwegian National Formulary), ed. Vilberg A. Oslo: Foreningen for utgivelse av Norsk legemiddelhåndbok, 2007; 1426-9.
26. British Medical Association and Royal Pharmaceutical Society of Great Britain. Appendix 1: Interactions: Coumarins. warfarin. In: British National Formulary 57 London: 2009: 738-9.
27. Martindale: the complete drug reference: warfarin sodium. Internet 2010. Available at (last accessed 4 March 2010).
28. Battistella M, Mamdami MM, Juurlink DN, Rabeneck L, Laupacis A. Risk of upper gastrointestinal hemorrhage in warfarin users treated with nonselective NSAIDs or COX-2 inhibitors. Arch Intern Med 2005; 165: 189-92.
29. Howard PA, Ellerbeck EF, Engelman KK, Patterson KL. The nature and frequency of potential warfarin drug interactions that increase the risk of bleeding in patients with atrial fibrillation. Pharmacoepidemiol Drug Saf 2002; 11: 569-76.
30. Lopez-Gonzalez E, Herdeiro MT, Figueiras A. Determinants of under-reporting of adverse drug reactions: a systematic review. Drug Saf 2009; 32: 19-31.
31. Strandell J, Bate A, Lindquist M, Edwards IR. Drug-drug interactions - a preventable patient safety issue? Br J Clin Pharmacol 2008; 65: 144-6.
32. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA 2008; 300: 2867-78.
33. Leung VW, Shalansky SJ, Lo MK, Jadusingh EA. Prevalence of use and the risk of adverse effects associated with complementary and alternative medicine in a cohort of patients receiving warfarin. Ann Pharmacother 2009; 43: 875-81.
34. Canter PH, Ernst E. Herbal supplement use by persons aged over 50 years in Britain: frequently used herbs, concomitant use of herbs, nutritional supplements and prescription drugs, rate of informing doctors and potential for negative interactions. Drugs Aging 2004; 21: 597-605.
35. Mehta DH, Gardiner PM, Phillips RS, McCarthy EP. Herbal and dietary supplement disclosure to health care providers by individuals with chronic conditions. J Altern Complement Med 2008; 14: 1263-9.
36. Cuzzolin L, Francini-Pesenti F, Zaffani S, Brocadello F, Pengo V, Bassi A, Benoni G. Knowledges about herbal products among subjects on warfarin therapy and patient-physician relationship: a pilot study. Pharmacoepidemiol Drug Saf 2007; 16: 1014-7.
37. Holbrook AM, Pereira JA, Labiris R, McDonald H, Douketis JD, Crowther M, Wells PS. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005; 165: 1095-106.
38. Ohlsson S, Holm L, Myrberg O, Sundstrom A, Yue QY. Noscapine may increase the effect of warfarin. Br J Clin Pharmacol 2008; 65: 277-8.